Skip to Content

Pacira BioSciences Inc PCRX

Morningstar Rating
$28.57 +0.10 (0.35%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PCRX is trading at a 34% discount.
Price
$28.32
Fair Value
$32.95
Uncertainty
Very High
1-Star Price
$41.42
5-Star Price
$13.93
Economic Moat
Qsll
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$28.47
Day Range
$28.0828.74
52-Week Range
$25.9448.58
Bid/Ask
$28.53 / $28.60
Market Cap
$1.33 Bil
Volume/Avg
48,952 / 498,951

Key Statistics

Price/Earnings (Normalized)
10.07
Price/Sales
1.97
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
715

Valuation

Metric
PCRX
Price/Earnings (Normalized)
10.07
Price/Book Value
1.59
Price/Sales
1.97
Price/Cash Flow
7.24
Price/Earnings
PCRX

Financial Strength

Metric
PCRX
Quick Ratio
3.55
Current Ratio
4.78
Interest Coverage
0.96
Quick Ratio
PCRX

Profitability

Metric
PCRX
Return on Assets (Normalized)
8.35%
Return on Equity (Normalized)
16.94%
Return on Invested Capital (Normalized)
9.72%
Return on Assets
PCRX

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ASpq$83.6 Bil
MKKGY
Merck KGaA ADRRhdsnwq$77.2 Bil
HLN
Haleon PLC ADRGpcz$38.6 Bil
VTRS
Viatris IncGxqk$11.6 Bil
RDY
Dr Reddy's Laboratories Ltd ADRNvdg$11.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRXkx$11.1 Bil
CTLT
Catalent IncDdjgtk$7.2 Bil
PRGO
Perrigo Co PLCBnmps$4.2 Bil
PBH
Prestige Consumer Healthcare IncSqgmg$3.0 Bil
CURLF
Curaleaf Holdings IncCqswy$2.8 Bil